-
公开(公告)号：US20220370491A1
公开(公告)日：2022-11-24
申请号：US17760908
申请日：2020-09-16
申请人： National University Corporation Tokyo Medical and Dental University , Takeda Pharmaceutical Company Limited
发明人： Takanori Yokota , Testuya Nagata , Hideki Furukawa , Takatoshi Yogo , Yasuo Nakagawa , Shigekazu Sasaki , Ryosuke Tokunoh , Tomohiro Seki , Kosuke Hidaka , Fumiaki Kikuchi , Osamu Kubo , Takahito Kasahara , Takuto Kojima , Junsi Wang , Norihito Tokunaga
IPC分类号： A61K31/713 , A61K47/54 , A61P25/00 , A61K9/00
摘要： The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.
-
公开(公告)号：US11440883B2
公开(公告)日：2022-09-13
申请号：US16811426
申请日：2020-03-06
发明人： Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike , Kohei Takeuchi , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tohru Miyazaki , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
IPC分类号： C07D211/56 , C07D211/36 , C07D405/06 , A61P25/26 , C07D409/10 , A61P25/00 , C07D205/04 , C07D207/14 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/06 , C07D405/10 , C07D405/12 , C07D413/06 , C07D417/06 , C07D417/14
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US11319286B2
公开(公告)日：2022-05-03
申请号：US16635408
申请日：2018-08-02
发明人： Tatsuhiko Fujimoto , Kentaro Rikimaru , Koichiro Fukuda , Hiromichi Sugimoto , Takahiro Matsumoto , Yuichi Kajita , Satoshi Mikami , Yuhei Miyanohana , Tatsuki Koike , Masaki Daini , Masaki Ogino , Kohei Takeuchi , Tohru Miyazaki , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
IPC分类号： C07D207/14 , C07D401/14 , C07D403/06 , A61P25/28
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20170226137A1
公开(公告)日：2017-08-10
申请号：US15421702
申请日：2017-02-01
发明人： Tatsuhiko Fujimoto , Kentaro Rikimaru , Koichiro Fukuda , Hiromichi Sugimoto , Takahiro Matsumoto , Norihito Tokunaga , Mariko Hirozane
IPC分类号： C07F7/18 , C07D211/24 , C07D401/14 , C07D405/06 , C07D413/06 , C07D405/14 , C07D401/06 , C07D409/12 , C07D401/12 , C07D405/12 , C07D417/06 , C07D417/14 , C07D211/56 , C07D409/06
CPC分类号： C07F7/1804 , C07D211/24 , C07D211/36 , C07D211/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/14
摘要： Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
-
公开(公告)号：US11713311B2
公开(公告)日：2023-08-01
申请号：US17550173
申请日：2021-12-14
发明人： Eiji Kimura , Masaki Ogino , Yasuhisa Kohara , Tomoko Ohashi , Tomohiro Kaku , Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito
IPC分类号： C07D409/12 , C07D401/12 , A61P25/28 , A61P25/24 , A61P25/06 , A61K9/20 , A61K9/48 , C07D231/56 , C07D235/06 , C07D249/18
CPC分类号： C07D409/12 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2095 , A61K9/4825 , A61K9/4858 , A61K9/4866 , A61P25/06 , A61P25/24 , A61P25/28 , C07D231/56 , C07D235/06 , C07D249/18 , C07D401/12
摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.-
公开(公告)号：US11702419B2
公开(公告)日：2023-07-18
申请号：US17201878
申请日：2021-03-15
发明人： Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito , Satoshi Mikami , Masaki Seto , Shinji Morimoto , Shinji Nakamura , Sachie Takashima , Masataka Murakami , Masaki Daini , Makoto Kamata , Minoru Nakamura , Yasufumi Wada , Hiroyuki Kakei , Kazuaki Takami , Taisuke Tawaraishi , Jumpei Aida , Kouichi Iwanaga , Satoshi Yamamoto
IPC分类号： C07D487/04 , A61K9/20 , A61K9/48 , C07D471/04 , A61P25/00
CPC分类号： C07D487/04 , A61K9/2095 , A61K9/4833 , A61P25/00 , C07D471/04
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20160159773A1
公开(公告)日：2016-06-09
申请号：US14909427
申请日：2014-07-29
发明人： Morihisa Saitoh , Takatoshi Yogo , Taku Kamei , Norihito Tokunaga , Yusuke Ohba , Takafumi Yukawa
IPC分类号： C07D401/14 , C07D413/14
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14
摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号：US12077522B2
公开(公告)日：2024-09-03
申请号：US17256330
申请日：2019-06-27
发明人： Tatsuhiko Fujimoto , Koichiro Fukuda , Hiromichi Sugimoto , Kentaro Rikimaru , Yoshihiro Banno , Takahiro Matsumoto , Norihito Tokunaga , Yoshihide Tomata , Yuji Ishichi , Shogo Marui , Tsuneo Oda , Tohru Miyazaki , Yasutaka Hoashi , Yasushi Hattori , Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike
IPC分类号： C07D401/14 , C07D211/56 , C07D405/14
CPC分类号： C07D401/14 , C07D211/56 , C07D405/14
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US11230541B2
公开(公告)日：2022-01-25
申请号：US16634402
申请日：2018-07-26
发明人： Eiji Kimura , Masaki Ogino , Yasuhisa Kohara , Tomoko Ohashi , Tomohiro Kaku , Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito
IPC分类号： C07D409/12 , C07D401/12 , C07D249/18 , A61P25/28 , A61P25/24 , A61P25/06 , A61K9/20 , A61K9/48 , C07D231/56 , C07D235/06
摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US11186565B2
公开(公告)日：2021-11-30
申请号：US16499432
申请日：2018-03-29
发明人： Seiji Miwatashi , Yasufumi Miyamoto , Koji Watanabe , Yayoi Nakayama , Yuko Hitomi , Jumpei Aida , Nobuyuki Takakura , Hideki Furukawa , Naoyoshi Noguchi , Yasuhiro Hirata , Kazuaki Takami , Norihito Tokunaga , Tomohiro Okawa , Akito Shibuya , Shizuo Kasai , Toshitake Kobayashi , Tsuyoshi Maekawa
IPC分类号： C07D401/12 , C07C59/72 , C07D211/22 , C07D213/64 , C07D401/10 , C07D401/14 , C07D413/10
摘要： Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.031 秒)
